Leerink Partners Remains a Buy on Century Therapeutics (IPSC)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
Nkarta (NKTX) Gets a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Hosted on MSN4h
Leerink Partners Downgrades 10x Genomics (TXG)
Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Fintel on MSN10h
Leerink Partners Upgrades Genmab A (GMAB)
Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...
CVS wins upgrade to buy as analyst sees more upside potential than its peers
"The stock remains at a discounted level versus historical ranges," Cherny said. "The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its ...
CVS Health reward 'positively skewed'
CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...